Dynavax TechnologiesDVAX
Market Cap: $1.49B
About: Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Employees: 408
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
394% more call options, than puts
Call options by funds: $6.71M | Put options by funds: $1.36M
150% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 5 (+3) [Q2]
2% less funds holding
Funds holding: 242 [Q1] → 237 (-5) [Q2]
3.04% less ownership
Funds ownership: 103.95% [Q1] → 100.91% (-3.04%) [Q2]
11% less repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 91
12% less capital invested
Capital invested by funds: $1.68B [Q1] → $1.48B (-$201M) [Q2]
14% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 36
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Goldman Sachs Paul Choi 60% 1-year accuracy 6 / 10 met price target | 32%upside $15 | Neutral Maintained | 8 Aug 2024 |
HC Wainwright & Co. Edward White 28% 1-year accuracy 34 / 121 met price target | 156%upside $29 | Buy Reiterated | 7 Aug 2024 |
HC Wainwright & Co. Edward White 28% 1-year accuracy 34 / 121 met price target | 156%upside $29 | Buy Reiterated | 28 Jun 2024 |